glp-1 conference About Based Therapeutics Summit: Emerging Indications Priya Jaisinghani, MD, DABOM, describes

Compared with a placebo or non-user comparator, this design minimizes immortal time bias and confounding by balancing disease severity or treatment eligibility in two groups, providing a more reliable real-world estimate of relative effects

Presented for research literature review only Jenkinson SG et al

Serious adverse events are rare but possible in individuals with undiagnosed pernicious anemia, cardiac conditions, or severe hepatic disease

Semaglutide vs Tirzepatide: Which GLP-1 Is Right for You

2) Dihexa has therapeutic potential to act as a treatment for various neurological disorders related to reduced synaptic connectivity, such as Alzheimers disease

We also screen for contraindications: a personal or family history of medullary thyroid carcinoma, MEN2 syndrome, severe gastroparesis, or pancreatitis